XXII 22nd Century Group Inc.

0.85
+0.05  (+7%)
Previous Close 0.79
Open 0.8
Price To Book 2.01
Market Cap 117,442,876
Shares 138,854,193
Volume 1,982,544
Short Ratio 10.81
Av. Daily Volume 1,112,734
Stock charts supplied by TradingView

NewsSee all news

  1. 22nd Century Group Reports First Quarter 2020 Financial Results

    22nd Century Group, Inc. (NYSE:XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, today reported

  2. 22nd Century Group Completes Successful Non-GMO Very Low Nicotine Content Tobacco Research Field Trials

    Research Validates New Non-GMO Methodologies for Reducing Nicotine in Tobacco Plants by up to 99% 22nd Century Group, Inc. (NYSE:XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on

  3. 22nd Century Group to Announce First Quarter 2020 Financial Results on May 7, 2020

    Williamsville, NY, April 28, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis

  4. FDA Announces Deadline to Submit Comments on 22nd Century Group's MRTP Application

    WILLIAMSVILLE, NY, April 17, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine content tobacco and

  5. 22nd Century Group to Hold Virtual Annual Meeting of Stockholders

    Williamsville, NY, April 08, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Tobacco Products Scientific Advisory Committee (TPSAC) to met February 14, 2020, regarding MRTP application.
VLN cigarettes
MRTP application

Latest News

  1. 22nd Century Group Reports First Quarter 2020 Financial Results

    22nd Century Group, Inc. (NYSE:XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, today reported

  2. 22nd Century Group Completes Successful Non-GMO Very Low Nicotine Content Tobacco Research Field Trials

    Research Validates New Non-GMO Methodologies for Reducing Nicotine in Tobacco Plants by up to 99% 22nd Century Group, Inc. (NYSE:XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on

  3. 22nd Century Group to Announce First Quarter 2020 Financial Results on May 7, 2020

    Williamsville, NY, April 28, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis

  4. FDA Announces Deadline to Submit Comments on 22nd Century Group's MRTP Application

    WILLIAMSVILLE, NY, April 17, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine content tobacco and

  5. 22nd Century Group to Hold Virtual Annual Meeting of Stockholders

    Williamsville, NY, April 08, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII) ("22nd Century" or "the Company"), a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis

  6. 22nd Century Group, Inc. Files 2019 Annual Report

    Maintains Strong Balance Sheet; Momentum Continues for Modified Risk Tobacco Product and Major Milestone Achieved in Hemp/Cannabis Research 22nd Century Group, Inc. (NYSE:XXII), a leading plant biotechnology company in

  7. 22nd Century Announces Important New Achievements with KeyGene

    Delivers Complete High-Quality Hemp/Cannabis Genome Sequence; Establishes New Proprietary Hemp/Cannabis Bioinformatics Platform WILLIAMSVILLE, N.Y. , March 11, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc.

  8. 22nd Century Group Adds to Leadership Team

    WILLIAMSVILLE, N.Y., March 10, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII), a plant biotechnology company that is a leader in reduced nicotine tobacco and hemp/cannabis plant genetics research, today

  9. Further Support for Reducing Nicotine in Cigarettes to Non-Addictive Levels: New Studies Confirm Use

    Williamsville, NY, March 04, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE:XXII), a plant biotechnology company that is a leader in reduced nicotine tobacco and hemp/cannabis plant research, announced that

  10. FDA Scientific Advisory Committee Discusses 22nd Century Group's Reduced Nicotine Cigarettes

    22nd Century Group and FDA presented information regarding 22nd Century's Modified Risk Tobacco Product marketing application for its proprietary VLN® and VLN® Menthol Reduced Nicotine Content Cigarettes 22nd Century

  11. 22nd Century Group's FDA Advisory Committee Meeting for Reduced Nicotine Content Cigarettes Brings New Standard for the Tobacco Industry

    22nd Century Group seeks Modified Risk Tobacco Product marketing authorization for its VLN® and VLN® Menthol Reduced Nicotine Tobacco Products 22nd Century Group, Inc. (NYSE:XXII)—a plant biotechnology company that is

  12. 22nd Century Group Appoints New Director and New Chairman

    Williamsville, NY, Jan. 13, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco